Steve CohenSell
APVO Common Stock · Transaction Jun 24, 2019 · Filed Jul 3, 2019 · Amount pending receipt enrichment
NASDAQ NMS - GLOBAL MARKET · APVO
+2.44% · +$0.1000 · Vol 3.8K
Market closed · last close 4:00 PM ET · price as of 15:59:51 ET
Aptevo Therapeutics Inc
Biotechnology
$4.19
Veridion Score
BETAMEDIUM CONF · 5/6 factorsStale score · Tue Aug 4 · completed session · 22h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET · APVO
MethodologyAPVO
Aptevo Therapeutics Inc
Stale score · Tue Aug 4 · completed session · 22h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET
BUY BIAS
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
81/ 100
Veridion Score
BUY BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Stale score · Tue Aug 4 · completed session · 22h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is APVO moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Aptevo Therapeutics Inc
PHARMACEUTICAL PREPARATIONSListed since
2016
Employees
33
Country
US
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$4.11
Day high
$4.19
Day low
$4.01
Previous close
$4.09
52W high
$44.10
-90.50% from high
52W low
$3.94
1% of range
Market cap
$5.1M
EPS
$-21.4300
Beta
0.79
Shares out
1.2M
Volume
3.8K
0.05× rel vol
Avg volume
70K
VWAP
$4.10
Price history computed in-house
1W
+5.28%
1M
-6.26%
3M
-13.79%
1Y
-90.50%
YTD
-55.57%
SMA 50 $4.56 · below
SMA 200 $10.04 · below
52W position 1%
APVO overview
Related filings and maps
Public disclosures
Congress activity in APVO
Official filing ↗
Federal contracts
APVO contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for APVO in this window.
Lobbying spend
APVO lobbying filings, year to date.
Registered lobbying filings matched to Aptevo Therapeutics Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for APVO in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for APVO.
Options
Sovereign unlock shows live options positioning for APVO.